CSBio CSBio

X
[{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Adocia"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sciwind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Sanofi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            In the terms of the agreement, Sanofi granted exclusive worldwide rights to Sciwind to develop, manufacture and commercialize Sanofi's GIP receptor agonists including XW003, for all applicable indications.

            Lead Product(s): XW003,Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: XW003

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Sciwind

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 30, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.

            Lead Product(s): Pramlintide,Exenatide

            Therapeutic Area: Nutrition and Weight Loss Product Name: PramExe

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY